Kornimate/medical-research-clean huggingface dataset:
retinal ganglion cell layer in patients with intracerebral processes

Conditions: Ganglion Cells

Summary: transsynaptic degeneration of the retinogeniculate pathways is well documented to occur in nonhuman primates when the cerebral lesion occurs even during adulthood. in case of humans, retrograde transsynaptic degeneration of the retinogeniculate pathways has been shown to occur following prenatal or perinatal lesions, but its occurrence after cerebral lesions in adults is considerable rare. it is, however, well established that retrograde transsynaptic degeneration affects other neural systems in humans even when the injury occurs during adulthood. some histopathological evidence points to the possibility of transsynaptic degeneration of the retinogeniculate pathway in humans even when the lesion occurs in adults, but the clinical significance is unknown.' purpose: to measure the retinal ganglion cell layer (gcl) in patients with visual field defects due to intracerebral processes. to correlate gcl with the localization and type of intracerebral lesion. to compare the gcl with the retinal nerve fibre layer (rnfl) to investigate, which of the 2 parameters is more sensitive to show retinal layer abnormalities. to correlate gcl with visual field defects and electrophysiological parameters.


Eligibility criteria:
inclusion criteria: * adult patients with intracerebral lesions within the central visual tract * associated visual field defects * investigations (oct, erg) possible exclusion criteria: * lesions within the optic nerve without extension in the optic tract * neurological disease * optic disc anomalies: glaucoma, nystagmus, high myopia
leucovorin and fluorouracil compared with observation in treating patients with colorectal cancer that has been surgically removed

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. it is not yet known whether chemotherapy is more effective than observation in patients who have had surgery to remove colorectal cancer. purpose: this randomized phase iii trial is studying leucovorin and fluorouracil to see how well they work compared to observation in treating patients with colorectal cancer that has been surgically removed.

objectives: * compare all-cause mortality in patients with resected colorectal cancer treated with adjuvant chemotherapy with l-leucovorin and fluorouracil vs observation. * compare the recurrence rates in patients treated with this regimen vs observation. * compare the effectiveness of a monthly 5-day schedule vs a once weekly schedule of l-leucovorin and fluorouracil in this patient population. outline: this is a randomized, open-label, multicenter study. patients are randomized to receive adjuvant chemotherapy (arm i) or undergo observation only (arm ii). * arm i: within 12 weeks of surgery, patients receive l-leucovorin iv followed by fluorouracil iv on days 1-5 every 4 weeks for 6 courses. alternatively, patients may receive l-leucovorin iv followed by fluorouracil iv on day 1 weekly for 30 weeks. * arm ii: patients undergo observation. patients are followed annually. projected accrual: a total of 2,500 patients (1,250 per arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: * completely resected stage ii or iii colorectal cancer * no distant metastases * no positive resection margins * no positive peritoneal washings patient characteristics: age: * 18 and over performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no clear definite indication for, or contraindication against, systemic chemotherapy with l-leucovorin and fluorouracil prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no concurrent chemotherapy in observation only arm endocrine therapy: * not specified radiotherapy: * concurrent radiotherapy allowed in adjuvant chemotherapy arm provided chemotherapy administered on the once weekly schedule surgery: * see disease characteristics

Keywords: stage ii colon cancer stage iii colon cancer stage ii rectal cancer stage iii rectal cancer
independent walking onset of children with cerebral palsy

Conditions: Cerebral Palsy

Summary: this study will focus the gait analysis, using an optoelectronic system, of children with unilateral cerebral palsy compared to typically developed children in the first 6 months of independent walking.


Eligibility criteria:
inclusion criteria: * maximum age of 3 years old * independent walking experience of maximum 6 months * ability to walk 5 m without falling or needing a technical assistance * a right or left hemiplegia in a predictive clinical context of a cp at the age of 2 years exclusion criteria: * history of lower limb musculoskeletal trauma in the last 6 months * a known skin allergy to any adhesive product * history of lower limb musculoskeletal surgery * history of btx injections into the lower limbs muscles in the last 3 months

Keywords: toddlers, gait
improving real-world function for persons with schizophrenia: a single-case experimental design

Conditions: Schizophrenia

Summary: existing treatment for individuals with psychosis primarily targets positive symptoms but has only modest effects on cognition and negative symptoms. cognitive strategy training shows promising effects in reducing negative symptoms and increasing activity initiation in individuals with schizophrenia. this project aims to investigate the effect of the perceive, recall, plan and perform (prpp) intervention in promoting effective use of cognitive strategies for adults with schizophrenia in performing their daily activities. twenty-seven individuals with schizophrenia will be recruited from sykehuset innlandet (innlandet hospital trust) and assessed using prpp prior to an eight-session prpp intervention. re-assessment will be conducted after the intervention, as well as at 3 and 6 months, to evaluate the long-term effects of the intervention. a single-case design will be used to investigate the intervention's effects. the primary outcome measure will be the prpp assessment, and the secondary outcome measure will be the goal attainment scale (gas). generalization measures will be used to evaluate whether there are relevant changes beyond the primary and secondary goals.


Eligibility criteria:
inclusion criteria: * dsm-5 diagnosis of schizophrenia, understand and speak norwegian, live in their own community context, but are patients in sykehuset innlandet ( innlandet hospital trust), either as outpatients or on discharge from inpatient care, a subjective experience of functional impairment and/or cognitive difficulties identified in an initial interview, and a stable state without any major medication change for at least two months before inclusion exclusion criteria: * major physical disability, a current substance abuse problem, and cognitive deficits of organic origin or mental retardation

Keywords: cognitive difficulties
automated setting of individualized sodium technology

Conditions: End Stage Renal Disease (ESRD)

Summary: the asist study is a medical device study testing the safety and efficacy of a new hemodialysis machine software in chronic haemodialysis patients. the software's intention is to reduce hemodialysis related symptoms such as unwell being, blood pressure changes by adapting the dialysis fluid ion concentration to the patients plasma ion concentration by conductivity measurement.


Eligibility criteria:
inclusion criteria: * subject must be in clinically stable condition as judged by the treating physician, and demonstrated by stable medical history, physical examination, and laboratory testing for 30 days prior to enrollment. * subject must be receiving hd or hemodiafiltration (hdf) for at least 30 days prior to study enrollment, be dialyzing a minimum of 3 times per week in an in-center setting and each treatment session must be between 3.5 and 5 hours in duration. * subject has a stable functioning vascular access (arteriovenous \[av\] fistula, graft, or dual-lumen tunneled catheter) based on the judgment of the treating physician and is performing dual-needle therapy with an actual blood flow rate of 250 - 400 ml/min. * subject has a pre-dialysis plasma sodium of ≥132 mmol/l for at least 60 days prior to study enrollment. * subject has achieved a dialysis dose of stdkt/vurea ≥ 2.1 within 60 days prior to enrollment. * subject has a pre-dialysis hemoglobin ≥ 90 g/l measured at screening. exclusion criteria: * female subjects who are pregnant, lactating, or planning to become pregnant during the study period. * subjects who have a significant psychiatric disorder or mental disability that could interfere with the subject's ability to provide informed consent and/or comply with protocol procedures. * subjects with a medical condition that the investigator thinks may interfere with the study objectives. * subjects with significant signs of access recirculation as judged by the treating physician.

Keywords: chronic kidney disease (ckd) end stage renal disease (esrd) chronic hemodialysis in-center hd sodium isotonic dialysis
the effect of early mobilization and fluid consumption on bowel movements after cholecystectomy

Conditions: Cholelithiases; Nursing Caries; Perioperative Complication; Bowel Ileus

Summary: objective: the aim of this study was to determine the effect of early mobilization with consumption of tea, coffee, and warm water on bowel movements in patients who had laparoscopic cholecystectomy surgery. design: the study was a single-center, parallel, randomized, controlled trial. setting: this study was carried out in the general surgery clinic of a university hospital in türkiye. metod: the participants were randomized into four equal groups: tea, coffee, arm water and control. at the 4th hour postoperatively, the patients in the intervention group were first mobilized after drinking 200 ml of tea, coffee or warm water within 15 minutes. the first mobilization and oral intake of the patients in the control group started at the 8th hour. bowel movements, mobilization time, first flatulence, first stool removal and hospital stay of the patients were followed up. data were collected with "patient information form", "glasgow coma scale", "patient mobilization follow-up form" and "patient undergone laparoscopic cholecystectomy surgery follow-up form". hypothesis: h0-a: early mobilization and tea consumption have no effect on the first flatulence time in patients who have undergone laparoscopic cholecystectomy surgery. h0-b: early mobilization and coffee consumption have no effect on the first flatulence time in patients who have undergone laparoscopic cholecystectomy. h0-c: early mobilization and consumption of warm water have no effect on the initial flatulence time in patients who have undergone laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: * to agree to participate in the study * to be the age is between 18 and 65 years old * to undergone laparoscopic cholecystectomy surgery * to have american society of anesthesiologists (asa) classification i or ii exclusion criteria: * to have a history of cesarean section, hysterectomy, extensive intra-abdominal surgery * to have metastatic disease, inflammatory bowel disease * to use drugs that may affect intestinal functions due to systemic diseases * to known allergy or sensitivity to coffee/caffeine * to having difficulty swallowing * to have mental disability or perception problems * to have a barrier to communication

Keywords: laparoscopic cholecystectomy early mobilization tea coffee water consumption intestines nursing
study of the performance of the keypath mrsa/mssa blood culture test - bta

Conditions: Bacteremia

Summary: in vitro identification of s. aureus,methicillin-sensitive s. aureus (mssa) and methicillin-resistant s. aureus (mrsa)from positive blood culture using microphage's bacteriophage-based diagnostic platform.

this is a multi-center clinical study to investigate the effectiveness of the performance of the keypath mrsa/mssa blood culture test - bta. the keypath test is performed directly on positive blood culture specimens from biomerieux bact/alert blood culture bottles. the microphage test will be compared to standards and market available tests with similar indications (comparators). it is estimated that the study will last 3-4 months depending on the accural rate at the institutions.

Eligibility criteria:
inclusion criteria: 1. blood culture samples determined to be gram-positive from subjects aged 18+, inclusive, with any of the following bottle types: * biomerieux bact/alert® standard aerobic and anaerobic * biomerieux bact/alert® fan aerobic and fan anaerobic 2. completion of the keypathtm bta test on the sample. 3. completion of the reference method for s. aureus identification (tube coagulase and remel staphaurex ) and completion of the reference method for methicillin resistance determination (30 µg cefoxitin disc diffusion) for s. aureus positive samples. exclusion criteria: 1. samples from blood culture positives over 24 hours from alarm 2. samples deemed contaminated. 3. violations and/or deviations from the keypathtm bta test protocol and/or other included test protocols under study.

Keywords: staphylococcus aureus methicillin resistant mrsa mssa blood culture diagnostic
safety and efficacy of electromagnetic navigation system assisted percutaneous endoscopic lumbar decompression

Conditions: Cervical Foraminal Stenosis; Cervical Disc Herniation

Summary: there is a shallow learning curve with teld (transforaminal endoscopic lumbar discectomy). the aim of this study is to assess the safety and efficacy of teld assisted by electromagnetic navigation for treating lumbar disc herniation (ldh).


Eligibility criteria:
inclusion criteria: 1. age≥18 and ≤80 years; 2. typical clinical symptoms and consistent imaging evidence of mono-radiculopathy ldh; or single level lss combined with disc herniation 3. recalcitrant pain despite proper conservative therapy (including analgesics, nsaids, corticoids infusion under ct guidance and physical therapy) for at least 3 months before surgery and/or neurological deficit in the territory of the irritated nerve root 4. vas pain ≥ 6/10 5. absence of significant instability; exclusion criteria: 1. serious underlying disease or mental illnesses 2. severe central stenosis, cauda equina syndrome, spinal instability, active infection, and serious calcified fragments 3. previous lumbar treatment with spinal surgery, ozone intervention, or radiofrequency ablation 4. unwilling or unable to participate in treatment and complete follow-up 5. multi-level disc pathology 6. mrc paresis \<4/5 7. pregnancy 8. participation in another clinical trial

Keywords: electromagnetic navigation herniated disc transforaminal endoscopic lumbar discectomy
a clinical study of efinopegdutide in people with compensated cirrhosis due to steatohepatitis (mk-6024-017)

Conditions: Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD; Metabolic Dysfunction-associated Steatotic Liver Disease; Metabolic Dysfunction-associated Steatohepatitis

Summary: researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (mash). mash was formerly called non-alcoholic steatohepatitis (nash). researchers want to learn if a study medicine called efinopegdutide can treat mash.the goals of this study are to learn: * if efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * about the safety of efinopegdutide and how well people tolerate it


Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: * has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (mash) * has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes exclusion criteria: the main exclusion criteria include but are not limited to the following: * has history of a liver disease other than mash, for example, hepatitis b or c, drug-induced liver disease, or autoimmune liver disease * has history of type 1 diabetes * had a bariatric surgical procedure less than 5 years before entry into the study * history of pancreatitis * major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke
routine preoperative antibiotic prophylaxis in modified radical mastectomy

Conditions: Surgical Infection

Summary: this is a randomized, double blinded, placebo-controlled trial on the routine use of preoperative antibiotic prophylaxis in modified radical mastectomy to evaluate the efficacy of preoperative prophylactic antibiotics in the prevention of surgical site infection (ssi) in patients undergoing modified radical mastectomy (mrm) for breast care.

a randomized, double blinded, placebo-controlled trial on the routine use of preoperative antibiotic prophylaxis in modified radical mastectomy to evaluate the efficacy of preoperative prophylactic antibiotics in the prevention of surgical site infection (ssi) in patients undergoing modified radical mastectomy (mrm) for breast care. women with breast cancer who will undergo elective mrm were recruited for the study. excluded were patients with significant co-morbid factors, for simultaneous breast reconstruction or bilateral oophorectomy, with intake of antibiotics within one week, with known allergy to cephalosporins, and those with local infection. patients were randomized to receive either transvenous cefazolin 1 gram or sterile water only within 30 minutes prior to skin incision. standard skin preparation and operative technique for mrm were carried out. wounds were assessed for the presence of ssi and other complications weekly for 30 days.

Eligibility criteria:
inclusion criteria: * women with histologically diagnosed breast cancer of age group 18-80 years old, ecog 0-1, clinical stage i to iiib, admitted to the surgery ward, who were scheduled for elective mrm. exclusion criteria: * women with significant co-morbid factors (diabetes mellitus, severe malnutrition, corticosteroid therapy), those scheduled for simultaneous breast reconstruction or bilateral oophorectomy, with intake of antibiotics within one week prior to surgery, with known allergy to cephalosporins, and those with local infection.

Keywords: antibiotic prophylaxis surgical site infection modified radical mastectomy prevention of surgical site infection (ssi) in patients undergoing mrm for breast cancer
single-center prospective study to validate the performance of the aktiia optical blood pressure monitoring (obpm) device at the wrist against ambulatory blood pressure monitoring (abpm)

Conditions: Blood Pressure; Hypertension

Summary: this study aims to assess the performances of optical blood pressure monitoring device, aktiia.product in the context of cardiac rehabilitation program.


Eligibility criteria:
inclusion criteria: * adult subjects (aged between 21 and 65) * subjects fluent in written and spoken french * subjects enrolled in a 12-weeks cardiac rehabilitation program * subjects agreeing to participate * subjects that have signed the informed consent form exclusion criteria: * subjects with tachycardia (heart rate at rest \> 120bpm) * subjects with atrial fibrillation * subjects with severe heart failure (lvef\<35%) * subjects with severe renal dysfunctions (egfr \< 30ml/min/1.73 m2) * subjects with pheochromocytoma * subjects with raynaud's disease * subjects with trembling and shivering * subjects with interarm systolic difference \> 15 mmhg * subjects with interarm diastolic difference \> 10 mmhg * subjects with arm paralysis * women in known pregnancy * subjects with an arteriovenous fistula * subjects with arm amputations * subjects with the upper arm circumference \> 64 cm * subjects with the wrist circumference \> 22 cm * subjects with the exfoliative skin diseases * subjects with lymphoedema
vascular changes in patients with aotic isthmus stenosis after interventional therapy

Conditions: Aortic Isthmus Stenosis

Summary: this controlled clinical study investigates arterial blood pressure and vascular remodling before and 4 weeks after catheter interventional treatment of re-stenosis of the aortic isthmus (recoarctatio aortae).

patients with treated aortic isthmus stenosis during their first year of life often develop a recoarctatio aortae (re-stenosis of the aortic isthmus) in the long term followed by arterial hypertension. the recoarctatio aortae can be treated during a cather intervention by balloon dilatation or stent implantation. patients with arterial hypertension often develop vascular remodeling with increased central systolic blood pressure and increased pulse pressure. vascular remodling predics cardiovascular events and increases mortality. vascular remodeling can be assessed non-invasively by using scanning laser doppler flowmetry (sldf)), pulse wave analysis and measurement of flow-dependent vasodilation. in this controlled clinical study we investigate arterial blood pressure and vascular remodling before and 4 weeks after catheter interventional treatment of recoarctatio aortae.

Eligibility criteria:
inclusion criteria: * male and female persons with recoarctatio aortae and planned interventional therapy (balloon dilatation or stent implantation) * adequate contraceptive methods in females with childbearing potential exclusion criteria: * other secondary causes for hypertension * treatment resistent arterial hypertension or uncontrolled hypertension (office bp ≥ 180/110 mmhg) * history of hypertensive enzephalopathy or intracerebral bleeding * diabetes mellitus * cataract * known renal, respiratory, hepatic, gastrointestinal, endocrine, metabolic, immunolic, hematologic, oncologic, neurologic or psychiatric diseases besides the diagnosis of artoic isthmus stenosis * one of the following diseases or conditions during the last 6 months: myocardial infaction, instable angina pectoris, cardiac insufficiency * pregnant or lactating woman or inadequate contraception (pearl-index ≥ 1%) * participation in another clinical study * drug or medication abuse * inadequate adherence or other condition preventing the patient from study participation (in the eyes of the treating physician)